CABA (Cabaletta Bio) Retained Earnings: $-560.47 Mil (As of Mar. 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $3.13
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Retained Earnings?

Cabaletta Bio CABA +1.29% 34 Retained Earnings is $-560.47 Mil as of Mar. 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cabaletta Bio's retained earnings for the quarter that ended in Mar. 2026 was $-560.47 Mil.

Cabaletta Bio's quarterly retained earnings declined from Sep. 2025 ($-475.04 Mil) to Dec. 2025 ($-516.96 Mil) and declined from Dec. 2025 ($-516.96 Mil) to Mar. 2026 ($-560.47 Mil).

Cabaletta Bio's annual retained earnings declined from Dec. 2023 ($-233.24 Mil) to Dec. 2024 ($-349.10 Mil) and declined from Dec. 2024 ($-349.10 Mil) to Dec. 2025 ($-516.96 Mil).


Cabaletta Bio  (NAS:CABA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Cabaletta Bio Retained Earnings Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Retained Earnings Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -112.59 -165.56 -233.24 -349.10 -516.96

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -385.04 -430.17 -475.04 -516.96 -560.47
CABA
34GF Score
Cabaletta Bio Inc CABA
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-560.47 Mil mean?
Cabaletta Bio (CABA) has a Retained Earnings of $-560.47 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cabaletta Bio and its competitors.
Is Cabaletta Bio's Retained Earnings too high?
Cabaletta Bio's current Retained Earnings is $-560.47 Mil. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Retained Earnings compare to RZLT and CCCC?
Cabaletta Bio's Retained Earnings of $-560.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cabaletta Bio and its competitors. Cabaletta Bio's current Retained Earnings is $-560.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Retained Earnings of $-560.47 Mil. The current Retained Earnings is $-560.47 Mil. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Retained Earnings is $-560.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.13
Price